Prometheus Biosciences, Inc. Common Stock
RXDX
RXDX was delisted on the 15th of June, 2023.
49 hedge funds and large institutions have $585M invested in Prometheus Biosciences, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 14 closing their positions.
57% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 14
38% more capital invested
Capital invested by funds: $426M → $585M (+$160M)
20% more funds holding
Funds holding: 41 → 49 (+8)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.35M |
| 3 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$4.77M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.3M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.59M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.58M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.57M |
| 4 |
Millennium Management
New York
|
-$3.4M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GPP
51
Great Point Partners
Greenwich,
Connecticut
| – | -$4.57M | -250,000 | Closed |
|
|
52
Millennium Management
New York
| – | -$3.4M | -186,157 | Closed |
|
53
Wellington Management Group
Boston,
Massachusetts
| – | -$2.74M | -150,193 | Closed |
|
|
MWNA
54
Marshall Wace North America
New York
| – | -$1.45M | -79,171 | Closed |
|
55
Goldman Sachs
New York
| – | -$1.08M | -59,083 | Closed |
|
56
Alyeska Investment Group
Chicago,
Illinois
| – | -$913K | -50,000 | Closed |
|
57
TD Asset Management
Toronto,
Ontario, Canada
| – | -$629K | -34,465 | Closed |
|
|
PCM
58
Pinz Capital Management
New York
| – | -$572K | -31,300 | Closed |
|
|
CCM
59
CAAS Capital Management
New York
| – | -$274K | -15,000 | Closed |
|
|
SCM
60
Silverarc Capital Management
Boston,
Massachusetts
| – | -$274K | -15,000 | Closed |
|
|
HP
61
Hound Partners
New York
| – | -$188K | -10,292 | Closed |
|
|
MS
62
Maven Securities
St Helier,
Jersey
| – | -$152K | -8,333 | Closed |
|
63
UBS Group
Zurich,
Switzerland
| – | -$14K | -776 | Closed |
|
RXDX Hedge Fund Activity: Q2 2021 in Review
49 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Prometheus Biosciences, Inc. Common Stock (RXDX) for Q2 2021, worth a combined $585M — up 38% from $426M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new RXDX positions and 14 closed out — a net gain of 8 holders — while 9 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $13.2M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $9.59M sold.
- 49 institutional investors held Prometheus Biosciences, Inc. Common Stock (RXDX) as of Q2 2021, up from 41 in Q1 2021.
- Funds reported $585M of Prometheus Biosciences, Inc. Common Stock stock for Q2 2021, up 38% quarter-over-quarter.
- 22 funds opened new Prometheus Biosciences, Inc. Common Stock positions in Q2 2021 and 14 closed out, a net change of +8 holders.
- The largest Prometheus Biosciences, Inc. Common Stock buyer in Q2 2021 was BlackRock, an estimated $13.2M added.
- The largest Prometheus Biosciences, Inc. Common Stock seller in Q2 2021 was T. Rowe Price Associates, an estimated $9.59M sold.
Based on aggregated 13F filings for Q2 2021.